eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 28/02/2012
SPC Brolene Eye Drops


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Brolene Eye Drops.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Propamidine isetionate 0.1% w/v.


Go to top of the page
3. PHARMACEUTICAL FORM

Eye drops.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Propamidine isetionate is an aromatic diamidine disinfectant which is active against Gram-positive non-spore forming organisms, but less active against Gram-negative bacteria and spore forming organisms. It also has antifungal properties. It may be used topically for the treatment of minor eye infections such as conjunctivitis and blepharitis.


Go to top of the page
4.2 Posology and method of administration

One or two drops up to four times daily. Medical advice should be obtained if there has been no significant improvement after two days.


Go to top of the page
4.3 Contraindications

Hypersensitivity to propamidine or any other component of the preparation.


Go to top of the page
4.4 Special warnings and precautions for use

If vision is disturbed or symptoms become worse during therapy, discontinue use and consult a physician.

If there is no significant improvement after two days' therapy, discontinue use and consult a physician.

The eye drops are unsuitable for use with hard or soft contact lenses.

The drops should be discarded 28 days after first opening for domiciliary use or, when used under hospital conditions, seven days after first opening.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Safety of use in pregnancy and lactation has not been established. Use during pregnancy and lactation only if considered essential by a physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

May cause blurring of vision on instillation. Patients should not drive or operate hazardous machinery unless vision is clear.


Go to top of the page
4.8 Undesirable effects

Hypersensitivity may occur.

Eye pain or irritation, usually in the form of a stinging or burning sensation, may also occur. In such cases, use should be discontinued immediately and a physician should be consulted.


Go to top of the page
4.9 Overdose

Topical overdosage not applicable. Oral ingestion of a full 10ml bottle is unlikely to cause any toxic effects.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Propamidine is a member of the aromatic diamidine group of compounds which possess bacteriostatic properties against a wide range of organisms. These diamidines exert antibacterial action against pyrogenic cocci, antibiotic resistant staphylococci and some Gram-negative bacilli, the activity of the diamidines being retained in the presence of organic matter such as tissue fluids, pus and serum.


Go to top of the page
5.2 Pharmacokinetic properties

No data available.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Ammonium chloride, Sodium chloride, Benzalkonium chloride, Sodium hydroxide, Water for injections.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

24 months

Once opened the drops should be discarded 28 days after first opening for domiciliary use or, when used under hospital conditions, 7 days after first opening.


Go to top of the page
6.4 Special precautions for storage

Store below 25oC.


Go to top of the page
6.5 Nature and contents of container

10 ml plastic dropper bottle and tamper-proof cap.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Sanofi

One Onslow Street

Guildford

Surrey

GU1 4YS


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0197


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

07 November 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

24 February 2012


Go to top of the page
LEGAL CLASSIFICATION

P



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/11316/SPC/


Active Ingredients/Generics

 
   propamidine isetionate